Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024.
Sign Up to like & getrecommendations! Published in 2024 at "JAMA pediatrics"
DOI: 10.1001/jamapediatrics.2024.5572
Abstract: Importance During the 2023-2024 respiratory syncytial virus (RSV) season in the United States, 2 new RSV prevention products were recommended to protect infants in their first RSV season: nirsevimab and Pfizer's maternal RSV vaccine. Postlicensure… read more here.
Keywords: 2023 2024; medically attended; nirsevimab effectiveness; rsv ... See more keywords
Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023–January 2024
Sign Up to like & getrecommendations! Published in 2024 at "Influenza and Other Respiratory Viruses"
DOI: 10.1111/irv.13311
Abstract: In September 2023, France was one of the first countries that started a national immunisation campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of paediatric intensive… read more here.
Keywords: respiratory syncytial; syncytial virus; nirsevimab effectiveness; paediatric intensive ... See more keywords
Nirsevimab Effectiveness Against RSV-Related Hospitalisations in Children Under 24 Months: A Test-Negative Case-Control Study in Portugal, 2024-2025.
Sign Up to like & getrecommendations! Published in 2025 at "Influenza and other respiratory viruses"
DOI: 10.1111/irv.70186
Abstract: We assessed Nirsevimab effectiveness (NE) against respiratory syncytial virus (RSV)‐related hospitalisation in eligible children ( read more here.
Keywords: rsv related; negative case; test negative; nirsevimab effectiveness ... See more keywords